A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)

NCT02461563 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus Infection

Interventions

DRUG: 200 mg MK-1075
DRUG: 400 mg MK-1075
DRUG: 800 mg MK-1075

Sponsor

Merck Sharp & Dohme LLC